Susquehanna Fundamental Investments’s GT Biopharma GTBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$81K Sell
942
-20
-2% -$1.76K ﹤0.01% 1472
2021
Q4
$88K Buy
962
+487
+103% +$72.9K ﹤0.01% 1342
2021
Q3
$96K Buy
+475
New +$143K ﹤0.01% 1628

Other funds holding GTBP

Susquehanna Fundamental Investments's GTBP Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its GT Biopharma (GTBP) stake by 2.1% in Q1 2022, selling an estimated $1.76K and leaving 942 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Susquehanna Fundamental Investments first reported a position in GTBP in Q3 2021 and has held it in 3 quarters since. The position peaked at $96K in Q3 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

  • Susquehanna Fundamental Investments held 942 shares of GT Biopharma worth $81K as of Q1 2022.
  • Susquehanna Fundamental Investments sold 20 GT Biopharma shares in Q1 2022, an estimated $1.76K.
  • GT Biopharma made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1472 holding.
  • Susquehanna Fundamental Investments first reported a position in GT Biopharma in Q3 2021 and has held it in 3 quarters since.
  • Susquehanna Fundamental Investments's GT Biopharma position peaked at $96K in Q3 2021.
  • 57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.